|
PubHealth.info®
(a subsidiary of
PakMed) presents scientific information mainly
based on abstracts of articles published on a variety of public health issues/topics,
particularly encompassing
population planning, disease prevention, maternal and child health,
and communicable and
non-communicable diseases (like HIV AIDS, malaria, etc) that are
affecting a significant portion of population in developing and
developed
countries. Here you can find abstracts of articles published on a variety of public health
topics under category "Contraception
(Birth Control) and Family Planning".
Contraception (birth control)
is a regimen of one or more actions, devices, or medications followed in
order to deliberately prevent or reduce the likelihood of a woman
becoming pregnant or giving birth. Therefore contraception is the
utilization of various and sundry surgical procedures, devices,
practices, agents, or drugs with the intention of preventing conception
or impregnation (pregnancy). Methods and intentions typically termed
birth control may be considered a pivotal ingredient to family
planning. Birth control is a controversial political and ethical
issue in many cultures and religions, and although it is generally less
controversial than abortion specifically. |
|
|
| CATEGORY: |
Contraception (Birth Control) and Family Planning |
| Risk for ovulation in women taking a low-dose oral contraceptive |
| (Microgynon) when receiving antibacterial treatment with a fluoroquinolone |
| Csemiczky G; Alvendal C; Landgren BM |
| ADVANCES IN CONTRACEPTION. 1996 Jun;12(2):101-9. |
| In the division of obstetrics and gynecology of Karolinska Hospital in Stockholm, Sweden, physicians conducted a |
| prospective, randomized, double-blind, crossover study among 20 healthy women aged 21-40 with regular menstrual |
| cycles. They aimed to evaluate a possible risk of escape ovulation in women using a combined oral contraceptive |
| (OC) (150 mcg levonorgestrel + 30 mcg ethinyl estradiol) (Microgynon, Schering AG) during treatment with ofloxacin |
| (Tarivid, Hoechst AG, Germany) for 7 days. One woman had to be excluded from the study because she had to be |
| treated with erythromycin due to pneumonia. The women were advised to use a mechanical contraceptive method |
| during the study period. Laboratory personnel measured follicle stimulating hormone and estradiol levels on tablet |
| days 5-8 and 19-21 and progesterone on days 19-21 during treatment with ofloxacin or placebo. Medical personnel |
| conducted ultrasound on one of days 5-10, 11-17, 18-24, and 25-28 to measure the number and diameter of ovarian |
| follicles. There was no evidence of escape ovulation during ofloxacin treatment. High estradiol levels up to 600 |
| pmol/l in conjunction with ovarian follicles of 15 mm or higher without any increase in progesterone levels above 3 |
| nmol/l occurred in four women. This ovarian activity with no escape ovulation occurred during placebo and ofloxacin |
| treatment, suggesting that interaction between the OC and ofloxacin did not account for the ovarian activity. In |
| conclusion, OC users on ofloxacin medication do not need to use other contraceptives during ofloxacin treatment. |
| (PubHealth.info Document ID: CONT2T 2074-06) |
| PubHealth.info NOTE: The author(s) of this article titled, "Risk for ovulation in women taking a low-dose oral |
| contraceptive (Microgynon) when receiving antibacterial treatment with a fluoroquinolone (ofloxacin)", is(are) |
| Csemiczky G; Alvendal C; Landgren BM. The source of this article is "ADVANCES IN CONTRACEPTION. 1996 |
| Jun;12(2):101-9.". This article was published in 1996 in English language(s). (PubHealth.info® Document ID: |
| CONT2T 2074-06. All rights reserved with PubHealth.info) PIN: 7074 |
|
|
|
© Copyrights PubHealth.info®,
an information portal on public health. All rights
reserved.
This page is optimized to be viewed by
Java script enabled Microsoft®
Internet Explorer 6 or later version, at screen resolution of 800 by 600 pixels. |
